Cohance Lifesciences Ltd share price logo

Cohance Lifesciences Ltd

NSE: COHANCE

BSE: 543064

Small Cap

Pharma Sector

₹493.30

+61.20

(+14.16%)

as on

bell
The current prices are delayed by 15 mins, login to check live prices.

Tech Chart

🔔 Leadership Alert

Cohance Lifesciences appointed Umang Vohra as Executive Chairman and Group CEO, effective May 1 and May 20, 2026, succeeding Vivek Sharma.

Cohance Lifesciences Stock Performance

as on April 28, 2026 at 9:31 pm IST

  • Day's Low

    Day's High

    ₹444.00
    ₹514.90
    downward going graph

    9.99%

    Downside

    4.38%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    ₹266.70
    ₹1,250.00
    downward going graph

    45.94%

    Downside

    153.40%

    Upside

    downward going graph

Cohance Lifesciences share price movements today

Previous Close
₹432.10
Open
₹444.45
Volume
4.09Cr
Upper Circuit
₹518.50
Lower Circuit
₹345.70
Day's Low - High
₹444.00 - ₹514.90
52 Week Low - High
₹266.70 - ₹1,250.00

Cohance Lifesciences Historical Returns

1 Month Return
+ 43.34 %
3 Month Return
+ 13.26 %
1 Year Return
-62.38 %
3 Year Return
-8.43 %
5 Year Return
-20.19 %

Cohance Lifesciences Fundamentals

as on April 28, 2026 at 4:01 pm IST

Market Cap

₹16,530.73 Cr

Return on Equity (ROE)

12.51

PE Ratio (TTM)

58.87

Return on capital employed (ROCE)

15.94

Industry PE ratio

42.13

Beta (LTM)

0.76

P/B Ratio

12.75

Dividend Yield

0

PEG Ratio

-13.41

Quarterly Earnings Growth YOY

-81.09

EPS (TTM)

10.4

Sector

Pharmaceuticals

Book Value

66.64

Cohance Lifesciences Stock Valuation

as on April 28, 2026 at 4:01 pm IST

Cohance Lifesciences in the last 5 years

  • Overview

  • Trends

Lowest (4.48x)

March 30, 2020

Industry (42.13x)

April 27, 2026

Today (58.87x)

April 27, 2026

Highest (139.71x)

November 5, 2024

LowHigh

Today’s Price to Earnings Ratio: 58.87x

Cohance Lifesciences Technical Analysis

Track how Cohance Lifesciences technical analysis has moved over time to understand its trends.

1 min
5 min
15 min
30 min
1 day
1 week
1 month

Technicals Summary

Bearish

Neutral

Bullish

Bearish

Moving Averages

Bearish

Neutral

Bullish

Bearish

Oscillators

Bearish

Neutral

Bullish

Bearish

Overall

Bearish11
Bullish1
Neutral3

Oscillators

Name

Value

Action

MACD level (12,26)
-1.48
Bearish
CCI (20)
-249.22
Bullish
RSI (14)
36.71
Neutral
Momentum (10)
-7
Bearish
ADI (14)
20.17
Neutral
Ultimate Oscillator (7,14,28)
55.01
Neutral

Moving Averages

Name

Value

Action

SMA (20)
490.12
Bearish
EMA (20)
489.96
Bearish
VWMA (20)
489.24
Bearish
SMA (50)
492.12
Bearish
EMA (50)
490.98
Bearish
SMA (200)
490.14
Bearish
EMA (200)
489.63
Bearish
KAMA (200)
491.48
Bearish
DEMA (200)
493.64
Bearish

Cohance Lifesciences Ltd vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Cohance Lifesciences with its industry peers.

Company
Analyst View
Market Cap(in ₹ Cr)
5 Year CAGRDebt to Asset Ratio
Net Profit(in ₹ Cr)
Yearly Revenue(in ₹ Cr)
Cohance Lifesciences Ltd image
Cohance Lifesciences Ltd
BUY16,530.73-4.04%0.682641,197
Jubilant Pharmova Ltd image
Jubilant Pharmova Ltd
BUY15,212.354%0.718367,234
Sun Pharma Advanced Research Company Ltd image
Sun Pharma Advanced Research Company Ltd
BUY4,761.38-3.31%1.88-34371
Rainbow Childrens Medicare Ltd image
Rainbow Childrens Medicare Ltd
BUY12,739.5835.73%0.672441,515
Poly Medicure Ltd image
Poly Medicure Ltd
BUY15,159.339.37%0.533381,669
See all

Market expectation of Cohance Lifesciences Stock

Common consensus of the market based on various publicly available news, publications,brokerage expectation and market data

BUY

62.50%

Buy

37.50%

Hold

0.00%

Sell

Cohance Lifesciences Stock’s Investor Sentiment and Interest

Investment in Cohance Lifesciences Ltd Shares on INDmoney has grown by 290.22% over the past 30 days, indicating increased transactional activity.

Time period: to

Change:290.22% versus previous 30 day period

Search interest for Cohance Lifesciences Ltd Stock has increased by 79% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:79% versus previous 30 day period

Cohance Lifesciences Ltd Quarterly Profit & Loss

Figures in Rupees Crores

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Sales
347.55
231.05
219.82
252.93
488.08
603.77
676.23
840.42
549.31
555.57
544.55
Other Income
10.67
19.84
14.34
17.05
19.41
16.19
21.56
12.05
14.17
15.6
6.16
Total Income
358.22
250.9
234.16
269.98
507.49
619.96
697.79
852.47
563.48
571.17
550.71
Expenses
180.58
133.09
153.74
179.59
362.98
398.4
438.86
626.98
445.4
434.62
454.06
Operating Profit
166.97
97.96
66.08
73.34
125.1
205.37
237.37
213.44
103.91
120.95
90.49
Operating Profit Margin %
48.04%
42.4%
30.06%
29%
25.63%
34.01%
35.1%
25.4%
18.92%
21.77%
16.62%
Profit Before Interest, Tax and Depreciation
177.63
117.8
80.42
90.4
144.51
221.56
258.93
225.49
118.08
136.55
96.65
Interest
1.15
0.5
2.16
2.3
10.2
9.61
10.8
10.45
10.18
8.76
9.11
Depreciation
12.54
11.89
12.79
17.25
31.28
37.79
43.56
54.17
45.14
44.02
46.94
Profit Before Tax
163.94
105.41
65.47
70.85
103.03
174.16
204.57
160.87
62.76
83.77
40.6
Tax Paid
43.35
25.84
18.72
17.48
27.66
35.92
51.09
43.72
16.36
17.38
11.58
Profit After Tax
120.59
79.56
46.75
53.37
75.37
138.24
153.48
117.15
46.4
66.39
29.02
Total Net profit including share of profit / Loss from associate company
120.59
79.56
46.75
53.37
75.37
138.24
153.48
117.15
46.4
66.39
29.02
EPS
4.74
3.13
1.84
2.1
1.98
3.63
4.02
3.16
1.28
1.94
0.96
Actual EPS
4.74
3.13
1.84
2.1
1.98
3.63
4.02
3.16
1.28
1.94
0.96
Adjusted EPS
4.74
3.13
1.84
2.1
1.98
3.63
4.02
3.16
1.28
1.94
0.96
Diluted EPS
4.74
3.13
1.84
2.1
1.97
3.61
4.01
3.1
1.27
1.93
0.96

Cohance Lifesciences Ltd Annual Profit & Loss

Figures in Rupees Crores

Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Sales
377.83
833.79
1,009.72
1,320.22
1,340.33
1,051.35
2,608.5
Other Income
0.6
66.33
67.97
133.49
46.36
61.91
69.21
Total Income
378.43
900.12
1,077.69
1,453.71
1,386.69
1,113.26
2,677.71
Expenses
206.28
452.19
569.24
740.8
766.17
645.54
1,827.22
Operating Profit
171.55
381.6
440.48
579.42
574.16
405.81
781.28
Operating Profit Margin %
45.4%
45.77%
43.62%
43.89%
42.84%
38.6%
29.95%
Profit Before Interest, Tax and Depreciation
172.15
447.93
508.45
712.92
620.53
467.72
850.49
Interest
2.79
19.92
9.14
6.23
12.81
7.45
41.06
Depreciation
11.5
23.51
31.64
39.1
47.99
54.6
166.8
Profit Before Tax
157.86
404.5
467.67
667.59
559.73
405.67
642.63
Tax Paid
48.59
87.51
105.34
213.78
148.44
105.39
158.39
Profit After Tax
109.27
317
362.34
453.8
411.29
300.28
484.24
Total Net profit including share of profit / Loss from associate company
109.27
317
362.34
453.8
411.29
300.28
484.24
EPS
8.59
24.91
14.23
17.83
16.16
11.8
12.79
Actual EPS
8.59
24.91
14.23
17.83
16.16
11.8
12.79
Adjusted EPS
4.3
12.46
14.23
17.83
16.16
11.8
12.79
Diluted EPS
8.59
24.91
14.23
17.83
16.16
11.8
12.68

Cohance Lifesciences Ltd Cash Flow

Figures in Rupees Crores

Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Net Cash from Operating Activities
50.4
406.92
382.55
330
457.2
358.48
288.16
Cash Flow from Investing Activities
-65.48
-413.46
-311.41
-136.21
-195.01
-362.26
-253.31
Cash Flow from Financing Activities
25.97
7.33
-75.67
-156.42
-241.96
-13.8
3.32
Net Cash Flow
10.9
0.79
-4.51
37.38
20.24
-17.57
38.17

Cohance Lifesciences Stock Shareholding Pattern

Numbers in percentages

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
May 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Promoters
60%
60%
60%
50.1%
50.1%
50.1%
50.1%
50.1%
66.41%
66.41%
57.49%
57.49%
57.49%
DII
9.23%
14.14%
15.94%
17.24%
17.42%
16.94%
16.68%
16.6%
11.02%
11.4%
20.82%
21.57%
21.79%
FII
0%
10.01%
10.14%
9.54%
9.8%
10.7%
10.84%
11.05%
7.38%
7.23%
6.51%
6.02%
5.59%
Government
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
Public
19.87%
15.84%
13.91%
23.1%
22.67%
22.25%
22.37%
22.23%
15.18%
14.95%
15.17%
14.92%
15.12%
Total Outstanding Shares
25,45,64,956
25,45,64,956
25,45,64,956
25,45,64,956
25,45,64,956
25,45,64,956
25,45,64,956
25,45,64,956
38,25,67,140
38,25,67,140
38,25,67,140
38,25,67,140
38,25,67,140
Total Shareholders
72,167
73,715
70,052
68,932
65,777
69,337
84,210
86,325
88,658
80,910
75,284
81,877
85,230

Mutual Funds that own Cohance Lifesciences Stock

Check out the Mutual Funds with significant holdings in Cohance Lifesciences.

Cohance Lifesciences Corporate Actions

View detailed summary of the earnings and dividend history of Cohance Lifesciences.

  • Cohance Lifesciences Ltd Earnings Results

    Cohance Lifesciences Ltd’s net profit fell -76.01% since last year same period to ₹36.72Cr in the Q3 2025-2026. On a quarterly growth basis, Cohance Lifesciences Ltd has generated -50.43% fall in its net profits since last 3-months.

    Read More about Earnings Results

  • Cohance Lifesciences Ltd Dividends September,2022

    In the quarter ending June 2022, Cohance Lifesciences Ltd has declared dividend of ₹5.00 per share on 02 Sep 2022 - translating a dividend yield of 3.05%.

    Read More about Dividends

Cohance Lifesciences News & Key Events

  • img

    Today's Timeline - 28 April

    09:19 AM

    -

    Cohance appoints Umang Vohra as Executive Chairman and Group CEO, succeeding Vivek Sharma, boosting stock by 20%.

Indices Featuring Cohance Lifesciences Stock

Check stock indices that include Cohance Lifesciences.

BSE Healthcare

₹44,563.26

-0.26 (▲114.11%)

Nifty Small 100

₹17,976.10

0.42 (▲75.45%)

Nifty MNC

₹31,890.85

-0.30 (▲94.65%)

S&P BSE 250 SmallCap

₹6,658.79

-0.05 (▲3.00%)

S&P BSE 400 MidSmallCap

₹12,050.26

-0.04 (▲4.65%)

S&P BSE SmallCap Select

₹8,159.95

0.42 (▲33.91%)

Nifty Smallcap 250

₹16,721.85

0.05 (▲8.30%)

Nifty Smallcap 50

₹8,788.50

0.45 (▲39.45%)

Nifty MidSmallcap 400

₹20,194.65

0.08 (▲16.85%)

BSE 500

₹35,650.27

-0.28 (▲100.82%)

Nifty 500

₹22,765.60

-0.24 (▲55.80%)

Insights on Cohance Lifesciences Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Retail Holding Up

    img

    Retail Investor have increased holdings from 14.92% to 15.12% in Mar 2026 quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, COHANCE stock has moved up by 19.6%

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 17.36% to 18.57% in Mar 2026 quarter

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 57.49% of holdings in Mar 2026 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Torrent Pharmaceuticals Ltd has given 155.4% return, outperforming this stock by 163.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Torrent Pharmaceuticals Ltd has given 26.5% return, outperforming this stock by 88.9%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 74.08 Cr → 36.72 Cr (in ₹), with an average decrease of 50.4% per quarter

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 6.02% to 5.59% in Mar 2026 quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 571.17 Cr → 550.71 Cr (in ₹), with an average decrease of 3.6% per quarter

About Cohance Lifesciences Ltd

Suven Pharmaceuticals Limited (SPL) is a biopharmaceutical company engaged in the development and manufacturing of New Chemical Entity (NCE) based Intermediates and Active Pharmaceutical Ingredients, Speciality Chemicals, and formulated drugs. In 2019, Suven Life Sciences Ltd. transferred the CRAMS business to the Company, and the equity shares of the Company were listed for trading in March 2020. The Board approved and recommended the issue of 1:1 bonus shares in August 2020, and the number of shares increased from 127,282,478 to 254,564,956. In 2021, Suven invested 120 crore in investing and has a capex plan of Rs.320crore. In 2022, the Company also filed 17 ANDAs for which 9 were approved and 8 products were launched. The Company acquired 100 stake in Casper Pharma Private Limited in 2022, making it a Wholly Owned Subsidiary. In this way, Suven Pharmaceuticals Limited is endeavouring to be the leading biopharmaceutical company in global markets.

Revenue: ₹544.55Cr as on December 2025 (Q3 FY26)
Net Profit: ₹29.02Cr as on December 2025 (Q3 FY26)
Listing date: 05 Mar, 2020
Chairperson Name: Annaswamy Vaidheesh
OrganisationCohance Lifesciences Ltd
IndustryPharmaceuticals
CEOAnnaswamy Vaidheesh
E-voting on sharesClick here to vote

FAQs

What is Cohance Lifesciences share price today?

Cohance Lifesciences share price today stands at ₹493.3 as on at the close of the market. Cohance Lifesciences share today touched a day high of ₹514.9 and a low of ₹444.

What is the 52 week high and 52 week low range for Cohance Lifesciences share?

Cohance Lifesciences touched a 52 week high of ₹1250 and a 52 week low of ₹266.7. Cohance Lifesciences share price today i.e. is closed at ₹493.3, which is -60.54% down from its 52 week high and 84.96% up from its 52 week low.

What is Cohance Lifesciences's market capitalisation today?

Cohance Lifesciences market capitalisation is ₹16,530.73 Cr as on .

How to buy Cohance Lifesciences shares?

To buy Cohance Lifesciences shares, you need to follow these steps:

  • Open a Demat account and Trading account on INDmoney
  • Fund your Trading account
  • Search for COHANCE or Cohance Lifesciences Ltd on the INDmoney app to check live prices of the stock
  • Click on Buy or SIP to place an order to invest in Cohance Lifesciences shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.

What is Cohance Lifesciences trading volume today?

Cohance Lifesciences trading volume is 4.09Cr as on . This means that 4.09Cr shares of Cohance Lifesciences were bought and sold on the stock market during today's trading session.